Compound class:
Synthetic organic
Comment: LY3509754 is an orally bioavailable, small molecule inhibitor of the proinflammatory cytokine IL-17A [1]. It was intended as an alternative to anti-IL-17A monoclonals for the treatment of psoriasis.
|
|
Immunopharmacology Comments |
Targeting IL-17A is a validated mechanism for anti-inflammatory action. In the clinical setting, although target engagement was determined, orally administered LY3509754 was poorly tolerated in humans [1]. |